BIOMAT Database Logo BIOMAT Database Logo

Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. 1989

B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Cancer Center, Wake Forest University, Winston-Salem, North Carolina 27103.

Forty-four evaluable patients with untreated acute myelogenous leukemia received twice-daily subcutaneous injections of low-dose ara-C (10 mg/m2) for less than or equal to 42 days. The median age was 72 years (range 53-87); 42 of 44 patients were greater than or equal to age 60. Ten patients (23%) had complete responses with a median duration of 9.9 months. Median survival was 3 months (range 0.6-31.2+) for all patients, and 19.5 (range 7.9-31.2+) for patients who attained complete responses. Cytoreduction occurred slowly with low-dose ara-C and five of ten patients who achieved complete remission did not develop marrow aplasia. Toxicity was predominantly related to infections associated with granulocytopenia. Nonhematologic toxicity was limited. Low-dose ara-C as used in this trial results in a complete response rate and a duration of response similar to those achieved with other treatments in elderly patients, but with reduced toxicity.

UI MeSH Term Description Entries
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Low-dose Ara-C treatment in elderly patients with acute myeloblastic leukemia.
January 1987, Haematology and blood transfusion,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
January 1987, Haematologica,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Treatment of acute myelogenous leukemia in aged patients with low-dose Ara-C (arabinosyl cytosine).
November 1984, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
[Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].
May 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly.
April 1990, Leukemia,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
December 2021, Blood advances,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
January 1990, Haematology and blood transfusion,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
May 2015, Blood,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
January 1987, Anticancer research,
B L Powell, and R L Capizzi, and H B Muss, and J D Bearden, and E S Lyerly, and D L Rosenbaum, and T M Morgan, and F Richards, and D V Jackson, and D R White
[Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia].
January 2001, Voprosy onkologii,
Copied contents to your clipboard!